Genome-wide assessment of shared genetic landscape of idiopathic pulmonary fibrosis and its comorbidities

• Published in: Human genetics Vol. 143; no. 9-10; pp. 1223 - 1239
• Main Authors: Yang, Yuanhao, Sheng, Yong H, Carreira, Patricia, Wang, Tong, Zhao, Huiying, Wang, Ran
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.10.2024; Springer Nature B.V
• Subjects: Apnea; Biomedical and Life Sciences; Biomedicine; Body mass index; Cardiovascular disease; Chronic obstructive pulmonary disease; Comorbidity; Coronary artery disease; Diabetes mellitus (non-insulin dependent); Drug development; Fibrosis; Gastroesophageal reflux; Gene clusters; Gene Function; Genetic factors; Genome-wide association studies; Genomes; Heart diseases; Human Genetics; Lung cancer; Lung diseases; Mental depression; Metabolic Diseases; Molecular Medicine; Original Investigation; Pulmonary artery; Pulmonary fibrosis; Sleep disorders
• ISSN: 0340-6717; 1432-1203; 1432-1203
• DOI: 10.1007/s00439-024-02696-9

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease accompanied by both local and systemic comorbidities. Genetic factors play a role in the development of IPF and certain associated comorbidities. Nevertheless, it is uncertain whether there are shared genetic factors underlying IPF and these comorbidities. To bridge this knowledge gap, we conducted a systematic investigation into the shared genetic architecture between IPF and ten prevalent heritable comorbidities (i.e., body mass index [BMI], coronary artery disease [CAD], chronic obstructive pulmonary disease [COPD], gastroesophageal reflux disease, lung cancer, major depressive disorder [MDD], obstructive sleep apnoea, pulmonary hypertension [PH], stroke, and type 2 diabetes), by utilizing large-scale summary data from their respective genome-wide association studies and multi-omics studies. We revealed significant (false discovery rate [FDR] < 0.05) and moderate genetic correlations between IPF and seven comorbidities, excluding lung cancer, MDD and PH. Evidence suggested a partially putative causal effect of IPF on CAD. Notably, we observed FDR-significant genetic enrichments in lung for the cross-trait between IPF and CAD and in liver for the cross-trait between IPF and COPD. Additionally, we identified 65 FDR-significant genes over-represented in 20 biological pathways related to the etiology of IPF, BMI, and COPD, including inflammation-related mucin gene clusters. Several of these genes were associated with clinically relevant drugs for the treatment of IPF, CAD, and/or COPD. Our results underscore the pervasive shared genetic basis between IPF and its common comorbidities and hold future implications for early diagnosis of IPF-related comorbidities, drug repurposing, and the development of novel therapies for IPF.